AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04255615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AI to analyze 3 D ultrasound
Description: AI to assess 3 D ultrasound to assess antral follicle count
Study NCT02156141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised high intensity training
Description: 8 weeks of supervised training
Study NCT02156141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional training
Description: 8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
Study NCT02156141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control period
Description: 8 weeks with no training.
Study NCT02156141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised High intensity training
Description: 8 weeks of unsupervised high intensity training.
Study NCT03421782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo PROSPECT internet-based CBT
Study NCT03421782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo POWER exercise intervention
Study NCT04387682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: β-glucan
Description: β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
Study NCT03293173 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CHOEP
Description: rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
Study NCT03293173 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
Study NCT00750646 — intervention group
Intervention type: DEVICE
Intervention: MEMS cap
Description: The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
Study NCT03627234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same Day Discharge
Description: Patients will be randomized to same day discharge
Study NCT03627234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight Stay
Description: Patients will be randomized to stay overnight
Study NCT04103021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port-A-Cath
Description: Totally implanted central venous access device
Study NCT01031888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical insulin eye drops
Description: Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
Study NCT01031888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional postoperative eye drops
Description: topical steroid, antibiotic and mydriatics
Study NCT01746290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulsePoint notification
Description: When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
Study NCT03555058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment escalation
Description: Treatment escalation per TDM and physician's decision.
Study NCT01497756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPP use
Description: Any abdominal pelvic pressure
Study NCT02866812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires assessing the state of fatigue, depression and anxiety
Study NCT01242514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily
Study NCT01242514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 150mg once daily
Study NCT01242514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg once daily
Study NCT03051958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mindfulness&exposure treatment
Description: See description under Arm.
Study NCT03051958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
Study NCT04561856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous 4mg
Study NCT01087762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT00681525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: One ABT-335 135 mg capsule QD for 10 days
Study NCT00681525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: One 80 mg tablet of atorvastatin QD for 10 days
Study NCT00681525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: One ezetimibe 10 mg tablet QD for 10 days
Study NCT01865253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation
Study NCT00944372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
Study NCT02559713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study NCT02225574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK-162
Description: Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Child and adolescent psychiatry and Epidemiology
Description: psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
Study NCT03553212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: 20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
Study NCT02918279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered once daily subcutaneously (s.c., under the skin)
Study NCT02918279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily subcutaneously (s.c., under the skin)
Study NCT02949583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Punica granatum Linn.
Description: Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
Study NCT02949583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
Study NCT02748954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thoughts
Description: Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week.
Study NCT02748954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities.
Description: Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated
Study NCT02748954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertiveness.
Description: Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
Study NCT02748954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only.
Study NCT02748954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Own Methods
Description: wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM902A 200-mg Capsules
Description: Taken orally with food twice daily
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM902A 400-mg Capsules
Description: Taken orally with food twice daily
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500-mg Capsules
Description: Taken orally with food twice daily
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Study NCT02847702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Study NCT05188781 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab combined Anlotinib
Description: Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
Study NCT00591500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
Study NCT00591500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
Study NCT02225574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.
Study NCT02225574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
Study NCT03356028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: salivary biological collection
Description: Saliva sampling will be done using a specific kit
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: qualitative analysis of the discourse
Description: two semi-structured interviews, the first with the teenager alone, the second with the lone parents
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenthood
Description: Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive alterations
Description: Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Impact on schooling
Description: collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
Study NCT03356028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep disorders and associated somatizations
Description: Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
Study NCT04561856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Perineural 4mg
Study NCT04561856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 2ml
Study NCT02756403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg
Study NCT02756403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200 mg
Study NCT01421121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
Study NCT01421121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200 U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
Study NCT01421121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Study NCT01421121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200U EV71 vaccine without adjuvant
Description: inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
Study NCT01421121 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml placebo, two doses, 28 days interval
Study NCT02691741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL
Description: Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study NCT02691741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA® tri IOL
Description: Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study NCT03531801 — intervention group
Intervention type: OTHER
Intervention: Pressure algometry and mapping referred pain areas
Description: The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
Study NCT05897918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid 500 MG
Description: Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
Study NCT01393184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab and Radiotherapy
Description: Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
Study NCT01393184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and Radiotherapy
Description: Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
Study NCT01933464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Study NCT03983928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT03983928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT03586245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferric pyrophosphate
Description: 57 Iron isotopically labeled FePP powder.
Study NCT03586245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Description: 58 Iron isotope intrinsically labeled Aspergillus oryzae.
Study NCT03586245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous sulfate
Description: 57 Iron isotopically labeled FeSO4 powder.
Study NCT02756403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg
Study NCT02756403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
Study NCT00094887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
Study NCT03101410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Selected participants will be randomly allocated to treatment group (gluten or gluten free).
Study NCT01205503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
Study NCT00094887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas will be delivered in the same manor as the experimental drug.
Study NCT01205503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline (used as a placebo) infused over the same time as mesna intervention
Study NCT03101410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten free
Description: Selected participants will be randomly allocated to treatment group (gluten or gluten free).
Study NCT03078634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-disciplinary clinic model
Description: Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
Study NCT03078634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard outpatient care
Description: Standard care provided in outpatient clinics staffed by GI doctors only
Study NCT01760109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin Sodium and Sulbactam Sodium
Description: 1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
Study NCT01205503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
Study NCT01205503 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.